The Optellum team is excited to be selected for the 2019 Digital Health Accelerator Cohort at TMCx, to be spend 4 months building our business with industry and clinical experts and mentors inside Texas Medical Center, the largest medical complex in the world.
The multidisciplinary team of experts from across the Texas Medical Center and the country reviewed more than 200 digital health solutions from around the world. They were impressed by the competitive pool and carefully considered multiple factors for each application, including innovativeness and strength of the technology, business model, market size, customer traction, and overall fit for the TMCx program.
TMCx is a program designed to meet the needs of startups at every stage while reducing barriers of access to hospital stakeholders and key opinion leaders across the Texas Medical Centre, which houses 54 medical institution, including the University of Texas M.D. Anderson Cancer Center, the No 1 cancer hospital in the world.
The program culminates on Thursday, June 6, 2019, with TMCx Demo Day, a closing ceremony where the Optellum team will pitch to over 400 investors, clinical experts, and industry leaders, with over a 1,000 more viewing remotely over the internet.
Optellum team and advisors took the lead role in preparing the winning bid, with Optellum Chairman, Prof Sir Michael Brady FRS named the Executive Chairman of the NCIMI consortium led by University of Oxford.
Optellum teams up with 15 NHS hospital trusts to develop AI decision support to guide optimal imaging follow-up, monitoring and treatment of cancer survivors. Potential patient benefits include speeding up the time to the right choice of effective therapy and avoiding inappropriate or unnecessary procedures that may cause harm to the patients (lung biopsies, surgeries, chemotherapy).
“We’re very excited to be part of this world-leading consortium and believe that, together, we can bring real benefits to the National Health Service patient and beyond.” says Dr. Timor Kadir, Optellum Chief Science and Technology Officer.
Read more here.
This week Optellum has been highlighted in three presentations at the IASLC World Conference on Lung Cancer in Toronto, Canada. On Tuesday, Dr. Peter van Ooijen, from University Medical Centre Groningen presented the results of the EIT Health LUCINDA project in a talk entitled “Lung Cancer Prediction Using Deep Learning Software: Validation on Independent Multi-Centre Data”. This collaboration between University Centre Groningen, Heidelberg University Hospital & The Thoraxklinik, Heidelberg, Oxford University Hospitals and Optellum, has validated for the first time a Deep Learning based lung cancer prediction model (Optellum LCP) on independent real-world datasets collected from three different centres. The results showed that overall classification remains very high (AUC=0.92 95%CI = 0.89-0.93) despite the very different patient populations. Rule-out performance was also excellent with 25.1% of benign patients being correctly ruled out from one CT scan with a Negative Predictive Value of 99.5%.
A second abstract, entitled “AI Based Malignancy Prediction of Indeterminate Pulmonary Nodules: Robustness to CT Contrast Media” presented as a poster-presentation with Oxford University Hospitals collaborators, examined the robustness of the Optellum Lung Cancer Prediction algorithm to the presence of contrast media in the CT study. Pulmonary nodules detected incidentally may present in a very wide variety of imaging studies; examples include CT angiography, contrast-enhanced diagnostic CT and PET/CT. Therefore it is important that any rule-out test is robust to the presence of contrast media in the image. The study found the Optellum LCP is robust to many contrast enhanced scans except for those with very high levels of enhancement.
The third abstract, entitled “Automatic Nodule Size Measurements Can Improve Prediction Accuracy Within a Brock Risk Model”, with Oxford University Hospitals, looked at the effect of using an automatic nodule volumetric segmentation algorithm of the classification performance of a logistic regression multi-parametric nodule malignancy risk model. Such models typically rely on the patient and nodule specific parameters to predict nodule malignancy, where nodule diameter is one of the key input parameters. The study found that utilizing automatic measurements of nodule diameter improved the classification performance from 86.5% to 88.5% on a dataset of 5373 nodules, an improvement of just over 2 AUC points.
Optellum welcomes an internationally renowned physician and scientist in early lung cancer diagnosis and treatment, Dr. Sam Janes MD, to join its Medical Advisory Board.
Prof. Janes works as a respiratory consultant at UCLH with a particular interest in Lung Cancer, mesothelioma, interventional and diagnostic bronchoscopy and early lung cancer detection. He is Head of Respiratory Research Department at UCL, director of the Lung Cancer Board for London Cancer, lead for Pulmonary at the International Society of Cellular Therapies and Vice-Chair of the National ‘Clinical Expert Group’ on Lung Cancer.
Prof. Janes’s research focuses on genetic and cellular changes in lung cancer pathogenesis. The ambition is that from this knowledge he can develop therapies detecting and targeting early lung cancers and thereby dramatically improve outcomes.
Prof. Janes runs the UCLH lung cancer team. He has developed a new endobronchial ultrasound service and performs all the invasive bronchoscopic techniques. He is running several clinical trials aiming to improve the patient journey of diagnosis and staging of lung cancers.
Prof. Janes joins a global team of physicians that help Optellum redefine early intervention in lung cancer, including
- Prof. Lutz Freitag MD, Interventional Pulmonologist, Hirslanden Klinik St. Anna & medical device inventor (100+ patents in pulmonary medicine)
- Prof. Fergus Gleeson MD, Professor of Radiology, University of Oxford (co-author of British Thoracic Society pulmonary nodule & NICE lung cancer guidelines)
- Prof. Pierre Massion MD, Pulmonologist, Cornelius Vanderbilt Chair in Medicine, Ingram Professor of Cancer Research, Vanderbilt Medical Center (co-author NCCN lung cancer guidelines)
- Prof. Reginald Munden MD, Chair of Radiology, Wake Forrest Baptist Health (ACR guidelines, M.D. Anderson Cancer Centre PI in the US National Lung Screening Trial).
- Prof. Matthijs Oudkerk MD, Chair of Radiology, University Medical Center Groningen (co-PI NELSON Study – Europe’s largest lung screening trial)
Join us at the American Thoracic Society 2018 Congress in San Diego, North America’s premier congress for pulmonary medicine, from May 20 till May 23.
- Meet us at Booth No 6 in the Clinical Trials section (AI & Lung Cancer)
Learn about NIHR IDEAL, the world’s first prospective multi-center trial of Lung Cancer Prediction AI, led by Oxford University Hospitals with the authors of NICE and British Thoracic Society guidelines.
- Visit our Scientific Poster (Tuesday May 22, 9.15am-11.15am)
Board 114: “Deep Learning-based Risk Stratification of Patients with Suspicious Nodules”
- See our Oral Presentation on the main scientific programme (Wednesday May 23, 2pm-2.15pm)
Dr. Timor Kadir, Chief Scientific & Technology Officer, presents a talk “Solid and Part-solid Lung Nodule Classification Using Deep Learning on the National Lung Screening Trial Dataset”.
Delighted to welcome Dr. Christine Berg, the co-Principal Investigator of the US National Lung Screening Trial (NLST), the biggest ever randomized clinical study, to learn more about Optellum and our work to redefine early interception of lung cancer with AI.
Optellum Scientific Advisory Board welcomes Leo Grady, an internationally recognized expert in healthcare machine learning and building medical imaging Software-as-a-Service (SaaS) products.
Leo Grady, Ph.D. (Senior Vice President of Engineering, HeartFlow) brings experience in building pioneering medical platforms and introducing agile medical device development methodologies at HeartFlow (Redwood City, California), a medical technology company that is redefining the way heart disease is diagnosed and treated, with the HeartFlow Analysis.
Dr. Grady has 15 years of experience in creating advanced medical imaging and machine learning-based software. Prior to joining HeartFlow, he worked at Siemens in the Corporate Research division focused on developing software for advanced imaging analytics and computer vision. In this role he created and led the development of innovative software products to extract complex information from a wide variety of medical imaging modalities, with a particular focus on cardiovascular and oncology applications.
He is internationally recognized for his work on advanced algorithms for medical imaging, computer vision and machine learning. Dr. Grady has published two books, over 100 peer-reviewed journal and conference papers and has over 300 issued or pending patents worldwide.
The Optellum Team looks forward to extending collaboration with Dr. Grady, which started over ten years ago during his tenure at Siemens Corporate Research, towards early interception of lung cancer and better lung health for all.
The government’s healthcare tsar, Sir John Bell, has told BBC News that AI could “save the NHS”. Sir Bell, the Regius Professor of Medicine, has highlighted Optellum as a company that has real potential to contribute to that goal. See full coverage in the worldwide BBC News here and in BBC iPlayer as broadcast on January 2.
Optellum welcomes one of world’s most visionary and influential thought leaders in lung cancer screening, Dr. Matthijs Oudkerk, to join its Medical Advisory Board.
Matthijs Oudkerk is the Professor and Chair of Radiology at the University Medical Center Groningen. He is the co-Principal Investigator of the NELSON study (Europe’s largest lung cancer screening trial) and the lead author of the official EU position statement, on how lung cancer screening shall be implemented in Europe (Lancet Oncology, November 2017)
Prof. Oudkerk joins a team of global leading lung cancer experts that help Optellum redefine early interception of lung cancer, including
- Fergus Gleeson MD, Professor of Radiology, University of Oxford (co-author of British Thoracic Society pulmonary nodule & NICE lung cancer guidelines)
- Pierre Massion MD, Pulmonologist, Cornelius Vanderbilt Chair in Medicine, Ingram Professor of Cancer Research, Vanderbilt Medical Center (a world-leading specialist in lung cancer biomarkers)
- Reginald Munden MD, Chair of Radiology, Wake Forrest Baptist Health (former M.D. Anderson Cancer Centre PI in the National Lung Screening Trial)